Bengaluru: On Saturday, Glenmark Pharmaceutical has launched an antiviral drug Favipiravir, named FabiFlu, for the treatment of COVID – 19 patients with mild and moderate infection. The drug was approved by the Drug Controller General of India.
“This approval comes at a time when cases in India are spiraling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
In a statement, the company said that, FabiFlu is the first approved oral medication for COVID – 19 treatment. They added, FabiFlu will lessen the intensity of the pressure caused by COVID – 19, and help in timely therapy.
The drug will be available as a prescription-based medication for Rs 103/ tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14.